Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed Partners With A*STAR to Build Out Cancer Database

NEW YORK (GenomeWeb) – Indivumed has partnered with Singapore's Agency for Science, Technology, and Research (A*STAR) to perform proteomics research, with the aim of building out the company's IndivuType global cancer database.

According to Indivumed, IndivuType is an online resource that combines genomic, transcriptomic, proteomic, precision proteomic, and digital histopathology data with clinical information from thousands of cancer patients. It also features bioinformatic and artificial intelligence tools for data analysis.

Under the terms of the deal, Indivumed and A*STAR's Institute of Molecular and Cell Biology will perform proteomic and phosphoproteomic analyses on thousands of tissue samples from the company's cancer biobank. The resulting data will be added to IndivuType. Additional terms were not disclosed.

Earlier this year, Hamburg, Germany-based Indivumed secured a €40 million ($46.6 million) loan from the European Investment Bank that is being used, in part, to build IndivuType.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.